Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.35 |
| ▸ | PGK1 | P00558 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PRNP | P04156 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8070842 | 0.84 | NQO2 (0.40) | NQO2CNR2GPR55GRM1PDE3B | |
| SCHEMBL8074487 | 0.79 | ALDH1A1 (0.39) | GRM1PDE3BPDE3AALDH1A1KDM4E | |
| SCHEMBL8071245 | 0.79 | CRHR1 (0.35) | GRM1PDE3BPDE3AP2RX7ALDH1A1 | |
| SCHEMBL8078338 | 0.79 | PDE4A (0.37) | GRM1PDE3BPDE3ASTING1MAPT | |
| SCHEMBL8161360 | 0.78 | LMNA (0.45) | GRM1ALDH1A1KDM4EHTTSTING1 | |
| SCHEMBL31423019 | 0.77 | ALDH1A1 (0.45) | ALDH1A1KDM4EGAAMAPT | |
| SCHEMBL13166990 | 0.75 | GRM1 (0.41) | GRM1ALDH1A1KDM4EHTTRXFP1 | |
| SCHEMBL13230278 | 0.74 | KDM4E (0.34) | GRM1PDE3BPDE3AALDH1A1KDM4E | |
| SCHEMBL669570 | 0.72 | GRM1 (0.50) | GRM1ALDH1A1PRNPRXFP1 | |
| SCHEMBL26547646 | 0.69 | NQO2 (0.50) | NQO2PDE3BPDE3APGK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778966-B2 | Quinolinone derivatives as PARP and tank inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-07-15 | — | — | US | disclosed |
| US-8778966-B2 | Quinolinone derivatives as PARP and tank inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-07-15 | — | — | US | disclosed |
| US-8404713-B2 | Quinolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-26 | — | — | US | disclosed |
| US-8404713-B2 | Quinolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-26 | — | — | US | disclosed |
| US-20130018017-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | VIALARD JORGE EDUARDO (BE) | 2013-01-17 | — | — | US | disclosed |
| US-20130018017-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | VIALARD JORGE EDUARDO (BE) | 2013-01-17 | — | — | US | disclosed |
| US-8299256-B2 | Quinolinone derivatives as PARP and TANK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-10-30 | — | — | US | disclosed |
| US-8299256-B2 | Quinolinone derivatives as PARP and TANK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-10-30 | — | — | US | disclosed |
| US-20100222348-A1 | QUINOLINONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222348-A1 | QUINOLINONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-02 | — | — | US | disclosed |
| US-20100168065-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-01 | — | — | US | disclosed |
| US-20100168065-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-01 | — | — | US | disclosed |
| WO-2009053373-A1 | QUINOLINONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-30 | — | — | WO | disclosed |
| WO-2008107478-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168065-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | PARP1, PARP11, PARP3 | NQO2 23/4885CNR2 2687/4885GPR55 2400/4885 |
| US-20130018017-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | PARP1, PARP11, PARP3 | NQO2 23/4885CNR2 2687/4885GPR55 2400/4885 |
| US-20100222348-A1 | QUINOLINONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP11 | NQO2 18/4885CNR2 2001/4885GPR55 2435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.